Rick E. Winningham - 14 Nov 2024 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol: TBPH
Transactions as of: 14 Nov 2024
Net transactions value: +$30,557
Form type: 4
Filing time: 19 Nov 2024, 21:08:38 UTC
Previous filing: 22 Aug 2024
Next filing: 22 Nov 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBPH	Ordinary Shares	Award	$30,557	+3,193	+0.18%	$9.57	1,827,092	14 Nov 2024	Direct	F1
holding	TBPH	Ordinary Shares						3,900	14 Nov 2024	As Custodian
holding	TBPH	Ordinary Shares						92,567	14 Nov 2024	By Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction is being reported late due to inadvertent administrative error. Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on November 14, 2024. Transaction was with the Issuer and did not involve an open market transaction.

Content

This transaction is being reported late due to inadvertent administrative error. Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on November 14, 2024. Transaction was with the Issuer and did not involve an open market transaction.